FDA approvals

Special Report

New Approved Treatments and Indications in Oncology

12/29/2020

Journal of Clinical Pathways

FDA Alerts

FDA Approves Selinexor in Combination With Bortezomib and Dexamethasone for MM

12/18/2020

Journal of Clinical Pathways

FDA Alerts

FDA Approves Atezolizumab for BRAF V600 Melanoma

07/31/2020

On July 30, 2020, the FDA approved atezolizumab (Tecentriq, Genentech) in combination with cobimetinib and vemurafenib for BRAF V600-mutated unresectable or metastatic melanoma. This approval is based on results...

On...

07/31/2020

Journal of Clinical Pathways

Research in Review

FDA Approval Process Flawed for Cancer Drugs

05/30/2016

JCP Editors

A study published in Mayo Clinic Proceedings has called into question how the Food and Drug Administration (FDA) uses surrogate endpoints in approvals for certain cancer medications. Surrogate endpoints are measures...

A...

05/30/2016

Journal of Clinical Pathways

Oncologists Call for New Metrics to Evaluate Effectiveness of Novel Treatments

03/17/2016

JCP Editors

At the 33rd Annual Miami Breast Cancer Conference (March 10-11, 2016; Miami Beach, FL), presenters called for new ways to evaluate the success of novel agents for the treatment of breast cancer. Although overall...

At the...

03/17/2016

Journal of Clinical Pathways